ROCKVILLE, Md., June 27, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that Gregory Glenn, M.D., Senior Vice President and Chief Medical Officer of Novavax, will make a plenary presentation on the company's respiratory syncytial virus (RSV) vaccine program on July 4, 2012 at the first Modern Vaccines Adjuvants and Delivery Systems conference in Copenhagen, Denmark. Dr. Glenn's presentation is entitled "Recombinant nanoparticle vaccine: Preclinical and clinical evaluation of an Sf9 insect cell-derived respiratory syncytial virus fusion protein," and will take place during the second plenary session of the conference. The conference was organized to address the urgent need for new adjuvants, delivery systems and technologies to support the development of new vaccines. Dr. Glenn is a member of the conference's advisory scientific panel. For more information about the conference program, please visit www.meetingsmanagement.co.uk.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle (VLP) and recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces potent vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India and LG Life Sciences of Korea. Together, these companies have worldwide commercialization capacity and the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website, www.novavax.com.
CONTACT: Frederick W. Driscoll
VP, Chief Financial Officer and Treasurer